---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269492"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:23:11.258790+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC

## Summary
- Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.
- Cash and investments $60.6M as of Sep 30, 2025; projected runway into Q1 2027.
- Net cash used in Q3 2025 was $10.8M, an increase of $0.3M from $10.5M in Q3 2024.
- Total operating expenses for Q3 2025 were $12.1M, down from $12.8M in the same prior-year period.
- Next clinical update from Phase 2 CRDF-004 trial expected in Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-269492
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/0001193125-25-269492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/crdf-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269492
- JSON: https://secwatch.observer/filing/0001193125-25-269492.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.